June 2008
Best Borrowers 2008: GlaxoSmithKline
The stars were aligned for GlaxoSmithKline’s $9 billion blockbuster issue, which smashed into the market and took several records with it.
If someone were to suggest going to the bond markets for the biggest ever corporate deal outside of the telecoms industry in the midst of the worst financial crisis for decades that is growing almost daily, that person would have been assigned close supervision. If that same person were to propose marketing such a deal with just a single investor conference call, he might well have been forcibly restrained. But UK pharmaceuticals company GlaxoSmithKline did just that with its $9 billion equivalent yankee issue on May 6.
Launched to fund a share buyback programme that was ramped up to £12 billion at the credit bull market’s 11th hour in July 2007, the four-tranche deal racked up a $17.8 billion order book in less than four hours. It was split into: 6.375% $2.75 billion due 2038, 5.65% $2.75 billion due 2018, 4.85%...
The rest of this article is only available to subscribers
If you are already a subscriber please log in now to view this article, by entering your username (email address) and password at the top right-hand side of this page.
If you are not a subscriber just subscribe today for full access to this article. You can do this either by clicking the link or calling +44 (0)207 779 8999.
If you are a trialist or subscriber, please enter your username and password at the top right-hand side of euromoney.com
Subscribers to Euromoney benefit from:
- 12 months access in print and online - on euromoney.com, read the latest issue early online, search for specific developments by region or sector, interrogate the results of Euromoney's benchmark polls, and view the archive dating back to 1996
- More than 30 specialist research guides free
- The results of Euromoney’s polls and surveys
- Tailored RSS news feeds direct to your desktop
- News delivered directly to your mobile device or PC
- Personalised email newsfeed of 'Top stories' and 'Breaking news'
Click here to subscribe